Alopecia News and Research RSS Feed - Alopecia News and Research

Alopecia is the lack or loss of hair from areas of the body where hair is usually found. Alopecia can be a side effect of some cancer treatments.
Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [More]
Halaven (eribulin mesylate) approved for treatment of liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. [More]
FDA clears for marketing first cooling cap to reduce chemotherapy-induced hair loss

FDA clears for marketing first cooling cap to reduce chemotherapy-induced hair loss

Today, the U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy. [More]
Combining medications may increase HBsAg loss in HBV patients

Combining medications may increase HBsAg loss in HBV patients

Combining tenofovir disoproxil fumarate with pegylated interferon alfa-2a may improve the chances of hepatitis B surface antigen loss in patients with hepatitis B virus infection, suggests a randomised trial. [More]
Heightened levels of psychological stress associated with skin complaints in college students

Heightened levels of psychological stress associated with skin complaints in college students

College is a stressful time in the lives of students, and a new study by researchers at the Lewis Katz School of Medicine at Temple University and Temple University found that heightened levels of psychological stress are associated with skin complaints. [More]
RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases. [More]
Paxman donates scalp cooling system to Huddersfield Royal Infirmary to raise awareness of breast cancer

Paxman donates scalp cooling system to Huddersfield Royal Infirmary to raise awareness of breast cancer

For UK-based Paxman – pioneers in scalp cooling – October is a poignant month. Not only is it Breast Cancer Awareness Month but it also marks fifteen years since the loss of Sue Paxman; the inspiration behind the scalp cooler. [More]
Inhibiting JAK family of enzymes promotes rapid hair growth, new study finds

Inhibiting JAK family of enzymes promotes rapid hair growth, new study finds

Inhibiting a family of enzymes inside hair follicles that are suspended in a resting state restores hair growth, a new study from researchers at Columbia University Medical Center has found. [More]
RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery. [More]
Paxman unveils commitment to ‘chase zero hair loss during chemotherapy’ at 2015 European Cancer Congress

Paxman unveils commitment to ‘chase zero hair loss during chemotherapy’ at 2015 European Cancer Congress

UK based Paxman – pioneers in scalp cooling – is unveiling their commitment to ‘chase zero hair loss during chemotherapy’ at the 2015 European Cancer Congress, Europe’s largest cancer platform being held in Vienna, Austria (September 25 – 29th, 2015). [More]
FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. [More]
Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

The use of arsenic trioxide instead of idarubicin in combination with all-trans retinoic acid is a feasible option in patients with acute promyelocytic leukaemia, regardless of risk level, suggests a phase III trial. [More]
Hedgehog blockade promising in myeloid malignancies

Hedgehog blockade promising in myeloid malignancies

Phase I trial results published in The Lancet Haematology show that the hedgehog signalling pathway antagonist PF-04449913 is tolerable and has activity in patients with haematological cancers. [More]
Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
Researchers successfully treat eczema patients using rheumatoid arthritis drug

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug recently shown to reverse two other disfiguring skin conditions, vitiligo and alopecia areata. The study is evidence of a potential new era in eczema treatment, they report. [More]

Cassiopea selects DATATRAK platform for significant global study

DATATRAK International, Inc., the leader in developing cloud-based, unified dClinical technologies and delivering related services for the clinical trials industry, today announced that Cassiopea S.p.A., the newly IPO'd former subsidiary of longtime partner Cosmo Pharmaceuticals SA has selected DATATRAK for a significant global study. [More]
RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA). [More]
Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers. [More]
Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma. [More]
Advertisement
Advertisement